Abstract:The aggregation of amyloid-beta protein (A beta) into fibrillary deposits is implicated in Alzheimer's disease (AD), and inhibiting A beta aggregation and clearing A beta fibrils are considered as promising strategies to treat AD. It has been reported that resveratrol (RSV) and epigallocatechin-3-gallate (EGCG), two of the most extensively studied natural polyphenols, are able to inhibit A beta fibrillization and remodel the preformed fibrillary aggregates into amorphous, non-toxic species. However, the mechanisms by which RSV inhibits A beta(42) aggregation and disrupts A beta(42) protofibril, as well as the inhibitory/disruptive mechanistic similarities and differences between RSV and EGCG, remain mostly elusive. Herein, we performed extensive all-atom molecular dynamics (MD) simulations on A beta(42) dimers (the early aggregation state of A beta(42)) and protofibrils (the intermediate of A beta(42) fibril formation and elongation) in the absence/presence of RSV or EGCG molecules. Our simulations show that both RSV and EGCG can bind with A beta(42) monomers and inhibit the dimerization of A beta(42). The binding of RSV with A beta(42) peptide is mostly via pi-pi stacking interactions, while the binding of EGCG with A beta(42) is mainly through hydrophobic, pi-pi stacking, and hydrogen-bonding interactions. Moreover, both RSV and EGCG disrupt the beta-sheet structure and K28-A42 salt bridges, leading to a disruption of A beta(42) protofibril structure. RSV mainly binds with residues whose side-chains point inwards from the surface of the protofibril, while EGCG mostly binds with residues whose side-chains point outwards from the surface of the protofibril. Furthermore, RSV interacts with A beta(42) protofibrils mostly via pi-pi stacking interactions, while EGCG interacts with A beta(42) protofibrils mainly via hydrogen-bonding and hydrophobic interactions. For comparison, we also explore the effects of RSV/EGCG molecules on the aggregation inhibition and protofibril disruption of the Iowa mutant (D23N) A beta. Our findings may pave the way for the design of more effective drug candidates as well as the utilization of cocktail therapy using RSV and EGCG for the treatment of AD.

(-)-Epigallocatechin-3-gallate (EGCG) inhibits fibrillation, disaggregates amyloid fibrils of alpha-synuclein, and protects PC12 cells against alpha-synuclein-induced toxicity

synuclein-induced toxicity

Epigallocatechin Gallate (EGCG) Inhibits Alpha-Synuclein Aggregation: A Potential Agent for Parkinson’s Disease

EGCG Attenuates Α-Synuclein Protofibril-Membrane Interactions and Disrupts the Protofibril

Epigallocatechin Gallate Destabilizes Α-Synuclein Fibril by Disrupting the E46-K80 Salt-Bridge and Inter-protofibril Interface.

Metal Chelator EGCG Attenuates Fe(III)‐induced Conformational Transition of Α‐synuclein and Protects AS‐PC12 Cells Against Fe(III)‐induced Death

Complex of EGCG with Cu(II) Suppresses Amyloid Aggregation and Cu(II)-Induced Cytotoxicity of Α-Synuclein.

Influence of EGCG on Α‐synuclein (αs) Aggregation and Identification of Their Possible Binding Mode: A Computational Study Using Molecular Dynamics Simulation

Neuroprotective effect of green tea extract (-)-epigallocatechin-3-gallate in a preformed fibril-induced mouse model of Parkinson's disease

Synergistic Effects of Negatively Charged Hydrophobic Nanoparticles and (−)-Epigallocatechin-3-gallate on Inhibiting Amyloid Β-Protein Aggregation

Effects of EGCG on Amyloid beta-Protein Fibrillogenesis and Cytotoxicity at Different pH Values

Isoliquiritigenin and liquiritin from Glycyrrhiza uralensis inhibit alpha-synuclein amyloid formation

Green Tea Extracts EGCG and EGC Display Distinct Mechanisms in Disrupting Aβ42 Protofibril.

Molecular Insights into the Inhibition and Disaggregation Effects of EGCG on Aβ40 and Aβ42 Cofibrillation

Epigallocatechin-3-gallate: A phytochemical as a promising drug candidate for the treatment of Parkinson's disease

Green tea extract EGCG plays a dual role in Aβ42 protofibril disruption and membrane protection: A molecular dynamic study.

Molecular mechanisms of resveratrol and EGCG in the inhibition of A<sub>42</sub> aggregation and disruption of A<sub>42</sub> protofibril: similarities and differences

Polyphenols in combination with β-cyclodextrin can inhibit and disaggregate α-synuclein amyloids under cell mimicking conditions: A promising therapeutic alternative

Molecular insight into conformational transition of amyloid β-peptide 42 inhibited by (-)-epigallocatechin-3-gallate probed by molecular simulations.

Protective effect of EGb761 against Aβ1-42 -induced SHSY5Y cells injury and blood-brain barrier disruption via regulating Akt/Nrf2 signaling pathway

Protective effects of galantamine against Abeta-induced PC12 cell apoptosis by preventing mitochondrial dysfunction and endoplasmic reticulum stress.